K. Vermeylen

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the european organization for research and treatment of cancer–‐genitourinary group study 30853

L. Denis, D. Newling, K. Vermeylen, 1993, Cancer.

Zoladex and Flutamide Versus Bilateral Orchiectomy

R. Sylvester, L. Denis, D. Newling, 1990, Cancer.

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.

S. Fosså, R. Sylvester, S. Kaye, 1995, British Journal of Cancer.

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.

R. Sylvester, A. V. van Oosterom, P. D. De Mulder, 1995, British Journal of Cancer.

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous testicular cancer.

R. Sylvester, A. V. van Oosterom, S. Kaye, 1997, British Journal of Cancer.

Eurocode - a Useful Network for Urologists

K. Vermeylen, P. Firket, 1990 .

Orchidectomy versus goserelin plus flutamide in patients with metastatic prostate cancer (EORTC 30853)

R. Sylvester, L. Denis, D. Newling, 1993, Cancer.

Vinblastine in metastatic renal cell carcinoma: EORTC phase II trial 30882. The EORTC Genitourinary Group.

K. Vermeylen, S. D. Fosså, J. Droz, 1992, European journal of cancer.

Orchidectomy versus Zoladex® plus Eulexin® in patients with metastatic prostate cancer (EORTC 30853)

L. Denis, D. Newling, K. Vermeylen, 1990, The Journal of Steroid Biochemistry and Molecular Biology.